Article Text

Download PDFPDF
Vitamin D status in prepubertal children with isolated idiopathic growth hormone deficiency: effect of growth hormone therapy
  1. Rasha Tarif Hamza1,
  2. Amira I Hamed2,
  3. Mahmoud T Sallam3
  1. 1 Department of Pediatrics, Faculty of Medicine, Ain Shams University, Cairo, Egypt
  2. 2 Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
  3. 3 Department of Clinical and Chemical Pathology, National Research Center, Cairo, Egypt
  1. Correspondence to Professor Rasha Tarif Hamza, Department of Pediatrics, Faculty of Medicine, Ain Shams University, Cairo 11371, Egypt; rashatarif_2000{at}


Few studies, and with controversial results, analyzed vitamin D status in children before and after growth hormone (GH) treatment. Thus, we aimed to assess vitamin D status in prepubertal children with idiopathic growth hormone deficiency (GHD), and to evaluate the effect of GHD and GH treatment on vitamin D levels. Fifty prepubertal children with isolated GHD were compared with 50 controls. All were subjected to history, anthropometric assessment and measurement of 25 hydroxyvitamin D (25(OH)D), serum calcium, phosphorous, alkaline phosphatase and parathyroid hormone (PTH) at diagnosis and 1 year after GH therapy. Serum 25(OH)D levels <30 ng/mL and 20 ng/mL were defined as vitamin D insufficiency and deficiency, respectively. 25(OH)D was lower in cases than controls. Forty per cent of children with GHD were 25(OH)D insufficient and 44% deficient, while 16% were sufficient at baseline. There was a positive correlation between 25(OH)D and peak GH levels. Peak GH was a significant predictor of 25(OH)D levels. After 1 year of GH therapy, 25(OH)D increased (18.42±5.41 vs 34.5±10.1 ng/mL; P<0.001). Overall, 22% of cases remained insufficient and 24% deficient, with an increase in prevalence of children with normal levels (54%; P<0.001). 25(OH) correlated negatively with PTH (r=−0.71, P=0.01). In conclusion, hypovitaminosis D is prevalent in children with GHD and significantly improved 1 year after GH therapy. 25(OH)D should be assessed in children with GHD at diagnosis and during follow-up.

  • 25-hydroxyvitamin D
  • calcium, dietary
  • growth hormone-releasing hormone

Statistics from


  • Contributors All authors equally contributed.

  • Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Parental/guardian consent obtained.

  • Ethics approval This study was approved by the Ethics Committee, Faculty of Medicine, Ain Shams University, Cairo, Egypt, which complies with the World Medical Association Declaration of Helsinki regarding ethical conduct of research involving human subjects and/or animals.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Presented at The manuscript was presented as an abstract at the ’Nutrition and Growth Conference' 2016 (

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.